Described are methods and devices for the generation of hydrogel particles with micrometer and submicrometer dimensions using oxygen-inhibited partial polymerization, and the particles generated therefrom. The described methods generate particles with dimensions independent of the starting polymerizable solution dimension, for example, a microdroplet. Further, microfluidic flow parameters (e.g. viscosity, flow rate) and photopolymerization process parameters (e.g. optical exposure intensity and duration) are controlled to generate particles with tunable crosslinking density-determined properties including elasticity, diffusivity, and biomolecular display for diverse applications such as drug delivery, tissue engineering cell scaffolds, and single- and multiple-cell therapeutics. Similarly, gradients of crosslinking density-determined properties can be created within single particles through the selection of optical exposure intensity and duration. In addition to conventional spherical shapes, a suite of non-spherical shapes may be generated by manipulating the dimensions of the microfluidic channels and other related physical and process parameters.

Disclosed herein, inter alia, are compositions and methods of modulating macrophage activity. Provided is a method of treating a disease (e.g., a macrophage-associated disease, autoimmune disease, inflammatory disease, or a cancer of an organ in the intraperitoneal cavity), the method including intraperitoneally administering to a subject in need thereof a therapeutically effective amount of a nanoparticle composition or pharmaceutical composition. Provided is a silica nanoparticle non-covalently bound to a plurality of nucleic acids, wherein the silica nanoparticle has a net positive charge in the absence of the plurality of nucleic acids. Provided is a pharmaceutical composition including a nanoparticle composition as described herein, and a pharmaceutically acceptable excipient.

Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.

This invention relates to amphiphile-polymer particles, compositions, methods of making, and methods of use thereof.

An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.

An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.

Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.

Microcapsules with a plurality of functionalities on the surface, an article of manufacture including microcapsules with a plurality of functionalities on the surface, and a method of forming a microcapsule with a plurality of functionalities on the surface which includes: providing one or more microcapsules; forming one or more wax particles, the wax particles including a wax core with the one or more microcapsules partially embedded in the wax core; functionalizing a first exposed surface of the one or more microcapsules; removing the functionalized one or more microcapsules from the wax core; and functionalizing a second exposed surface of the functionalized one or more microcapsules, the second exposed surface previously embedded in the wax core are disclosed.

A microcapsule suspension for treating a protein-containing surface includes droplets of a dispersed water-immiscible core phase, an aqueous continuous phase, and a wall surrounding each core phase droplet. The wall includes the salt formed from at least one Lewis base reactant and at least one Lewis acid reactant, wherein at least one Lewis base reactant or Lewis acid reactant is amphiphilic and wherein at least one Lewis acid reactant is selected from the group consisting of proteins, protein hydrolysates, charged amino acids, and water-soluble salts of any of these.

Pharmaceutical compositions and stable nano-suspensions comprising mifepristone and at least one pharmaceutically acceptable excipient, which exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. Manufacturing process and methods of use are also provided. The pharmaceutical compositions are used for prevention, treatment or prophylaxis of disorders in human patients in need thereof. Oral pharmaceutical compositions of mifepristone, methods for their administration, processes for thei r production, and use of these compositions are described for the treatment of diseases for which mifepristone is indicated.